2. Metabolic Enzyme/Protease Cell Cycle/DNA Damage GPCR/G Protein
  3. Endogenous Metabolite DNA/RNA Synthesis P2Y Receptor
  4. Uridine triphosphate

Uridine triphosphate  (Synonyms: UTP; Uridine 5'-triphosphate)

Cat. No.: HY-107372
Handling Instructions

Molarity Calculator

Uridine triphosphate (UTP) is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate activates membrane-bound P2Y2 receptors.

The free form of the compound is prone to instability, it is advisable to consider the stable salt form (Uridine triphosphate trisodium salt) that retains the same biological activity.

For research use only. We do not sell to patients.

Uridine triphosphate Chemical Structure

Uridine triphosphate Chemical Structure

CAS No. : 63-39-8

Size Price Stock
5 mg USD 32 Ask For Quote & Lead Time
10 mg USD 50 Ask For Quote & Lead Time
50 mg USD 80 Ask For Quote & Lead Time
100 mg USD 120 Ask For Quote & Lead Time

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Other In-stock Forms of Uridine triphosphate:

Uridine triphosphate Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Uridine triphosphate (UTP) is a pyrimidine nucleoside triphosphate that is used as a substrate to synthesize RNA or as an energy source in metabolic reactions. Uridine triphosphate activates membrane-bound P2Y2 receptors[1][2].

IC50 & Target

Human Endogenous Metabolite

 

In Vitro

Uridine triphosphate (UTP) (0, 10, 100, 250, 500, and 1000 µM; 2, 4, 6, 8, 10, and 12 h) enhances RT4-D6P2T cells migration and wound repair. Uridine triphosphate induces Schwannoma cell migration through activation of P2Y2 receptors and through the increase of extracellular MMP-2 activation and expression[2].
Uridine triphosphate (UTP) evokes MAPK phosphorylation in a biphasic pattern MAPK phosphorylation, with an early transient phosphorylation 5 min after treatment, and a late and sustained phosphorylation that appeared at 6 h and lasted up to 24 h[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Uridine triphosphate Related Antibodies

Western Blot Analysis[2]

Cell Line: RT4-D6P2T cells
Concentration: 250 µM
Incubation Time: 5 min, 45 min, 2 h, 6 h, 12 h, 24 h, 48 h
Result: Induces biphasic MAPK phosphorylation.
In Vivo

Uridine triphosphate (UTP) (0.44-4.4 µg/kg; i.v.; once) reduces infarct size and improves rat heart function after myocardial infarct[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Male Wistar rats (250-300 g; 2-3 months) with myocardial infarction (MI)[3]
Dosage: 0.44 µg/kg 30 min before MI, and 4.4 µg/kg i.v. 24 h prior to MI.
Administration: i.v.; once
Result: Reduced infarct size and improves rat heart function after myocardial infarct.
Clinical Trial
Molecular Weight

484.14

Formula

C9H15N2O15P3
CAS No.
Appearance

Solid

Color

White to off-white

SMILES

O=C(N1[C@H]2[C@H](O)[C@H](O)[C@@H](COP(O)(OP(OP(O)(O)=O)(O)=O)=O)O2)NC(C=C1)=O
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage
Powder -20°C 3 years
4°C 2 years

*The compound is unstable in solutions, freshly prepared is recommended.

Solvent & Solubility
In Vitro: 

H2O : ≥ 150 mg/mL (309.83 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.0655 mL 10.3276 mL 20.6552 mL
5 mM 0.4131 mL 2.0655 mL 4.1310 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 100 mg/mL (206.55 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 2.0655 mL 10.3276 mL 20.6552 mL 51.6380 mL
5 mM 0.4131 mL 2.0655 mL 4.1310 mL 10.3276 mL
10 mM 0.2066 mL 1.0328 mL 2.0655 mL 5.1638 mL
15 mM 0.1377 mL 0.6885 mL 1.3770 mL 3.4425 mL
20 mM 0.1033 mL 0.5164 mL 1.0328 mL 2.5819 mL
25 mM 0.0826 mL 0.4131 mL 0.8262 mL 2.0655 mL
30 mM 0.0689 mL 0.3443 mL 0.6885 mL 1.7213 mL
40 mM 0.0516 mL 0.2582 mL 0.5164 mL 1.2909 mL
50 mM 0.0413 mL 0.2066 mL 0.4131 mL 1.0328 mL
60 mM 0.0344 mL 0.1721 mL 0.3443 mL 0.8606 mL
80 mM 0.0258 mL 0.1291 mL 0.2582 mL 0.6455 mL
100 mM 0.0207 mL 0.1033 mL 0.2066 mL 0.5164 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Uridine triphosphate Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Uridine triphosphate63-39-8UTP Uridine 5'-triphosphateEndogenous MetaboliteDNA/RNA SynthesisP2Y ReceptorInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Uridine triphosphate
Cat. No.:
HY-107372
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.